Skip to main content

Table 3 Efficacy of lenvatinib in patients with uHCC

From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in China

  LEN monotherapy
(n = 39)
LEN combination (n = 72) LEN + PD1 (n = 30) LEN + HAIF/TACE (n = 24) LEN + PD1 + HAIF/TACE (n = 16)
CR 0 2/3% 1/3% 0 0
PR 6/15% 19/26% 10/33% 7/29% 2/13%
SD 21/54% 42/58% 12/40% 17/71% 12/75%
ORR 15% 29% 36% 29% 13%
DCR 69% 87% 76% 100% 88%
  1. Data are presented as n/%
  2. LEN, lenvatinib; PD-1, programmed cell death protein-1 targeted immunotherapy; HAIF, hepatic arterial infusion with drug filtration; TACE, transcatheter arterial chemoembolization; CR, complete response; ORR, objective response rate; DCR, disease control rate; PR, partial response; SD, stable disease